Analysts expect HCA Healthcare Inc (NYSE:HCA) to announce $11.29 billion in sales for the current quarter, Zacks reports. Ten analysts have provided estimates for HCA Healthcare’s earnings. The lowest sales estimate is $11.11 billion and the highest is $11.42 billion. HCA Healthcare posted sales of $10.70 billion in the same quarter last year, which suggests a positive year over year growth rate of 5.5%. The firm is scheduled to announce its next quarterly earnings results before the market opens on Tuesday, October 30th.
According to Zacks, analysts expect that HCA Healthcare will report full year sales of $46.22 billion for the current year, with estimates ranging from $46.03 billion to $46.46 billion. For the next year, analysts expect that the firm will report sales of $48.52 billion, with estimates ranging from $47.68 billion to $49.82 billion. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover HCA Healthcare.
HCA Healthcare (NYSE:HCA) last announced its earnings results on Wednesday, July 25th. The company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.16 by $0.13. The firm had revenue of $11.53 billion for the quarter, compared to the consensus estimate of $11.32 billion. HCA Healthcare had a net margin of 6.21% and a negative return on equity of 61.68%. The business’s quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.73 EPS.
Several research analysts recently commented on the stock. Jefferies Financial Group lifted their target price on shares of HCA Healthcare to $155.00 and gave the stock a “buy” rating in a report on Friday, September 21st. Robert W. Baird lifted their target price on shares of HCA Healthcare from $130.00 to $150.00 and gave the stock a “positive” rating in a report on Thursday, September 20th. Bank of America lifted their target price on shares of HCA Healthcare from $125.00 to $135.00 and gave the stock an “underperform” rating in a report on Tuesday, September 18th. Royal Bank of Canada lifted their target price on shares of HCA Healthcare to $150.00 and gave the stock an “outperform” rating in a report on Monday, September 10th. Finally, Argus lifted their target price on shares of HCA Healthcare to $150.00 and gave the stock a “buy” rating in a report on Friday, September 7th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and eighteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $131.62.
HCA traded down $0.09 during trading on Monday, hitting $138.88. The stock had a trading volume of 992,100 shares, compared to its average volume of 1,912,638. The company has a market capitalization of $48.14 billion, a PE ratio of 21.07, a price-to-earnings-growth ratio of 1.23 and a beta of 0.49. HCA Healthcare has a 12 month low of $71.18 and a 12 month high of $141.05. The company has a debt-to-equity ratio of -7.64, a current ratio of 1.36 and a quick ratio of 1.15.
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 28th. Stockholders of record on Tuesday, September 4th were issued a dividend of $0.35 per share. The ex-dividend date of this dividend was Friday, August 31st. This represents a $1.40 annualized dividend and a dividend yield of 1.01%. HCA Healthcare’s payout ratio is 21.24%.
In other news, insider Charles J. Hall sold 34,125 shares of the business’s stock in a transaction dated Friday, August 3rd. The shares were sold at an average price of $129.93, for a total transaction of $4,433,861.25. Following the transaction, the insider now owns 98,124 shares in the company, valued at approximately $12,749,251.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Kathryn A. Torres sold 1,530 shares of the business’s stock in a transaction dated Friday, July 27th. The stock was sold at an average price of $124.47, for a total transaction of $190,439.10. Following the transaction, the senior vice president now owns 9,307 shares in the company, valued at approximately $1,158,442.29. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 170,257 shares of company stock worth $21,118,053. Insiders own 2.80% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Smithfield Trust Co. increased its stake in HCA Healthcare by 541.9% in the second quarter. Smithfield Trust Co. now owns 995 shares of the company’s stock valued at $102,000 after acquiring an additional 840 shares during the period. Signet Financial Management LLC bought a new stake in HCA Healthcare in the second quarter valued at about $137,000. Adviser Investments LLC bought a new stake in HCA Healthcare in the second quarter valued at about $159,000. Bridgeworth LLC bought a new stake in HCA Healthcare in the second quarter valued at about $173,000. Finally, Hyman Charles D bought a new stake in HCA Healthcare in the second quarter valued at about $205,000. 70.40% of the stock is currently owned by institutional investors and hedge funds.
About HCA Healthcare
HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.
Recommended Story: Initial Public Offering (IPO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.